Arrowhead Pharmaceuticals, Inc. $ARWR Holdings Decreased by Tidal Investments LLC

Key Points

• Tidal Investments cut its Arrowhead Pharmaceuticals stake by 82.6% in the second quarter, selling 39,505 shares and retaining 8,325 shares valued at approximately $679,000. Institutional investors collectively own 62.61% of ARWR.
• Arrowhead reported quarterly revenue of $75.25 million, up 171% year over year but above estimates, while its loss of $1.36 per share missed consensus by $0.13. Analysts expect a full-year loss of $3.62 per share.
• Despite recent insider selling and a share price of $66.48, analysts maintain a “Moderate Buy” consensus with an average price target of $99.15; the company develops RNAi-based therapies using its TRiM delivery platform.

Tidal Investments LLC lowered its stake in Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR - Free Report) by 82.6% in the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 8,325 shares of the biotechnology company's stock after selling 39,505 shares during the quarter. Tidal Investments LLC's holdings in Arrowhead Pharmaceuticals were worth $679,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Versant Capital Management Inc increased its stake in shares of Arrowhead Pharmaceuticals by 285.1% during the second quarter. Versant Capital Management Inc now owns 335 shares of the biotechnology company's stock valued at $27,000 after acquiring an additional 248 shares during the period. Carolina Wealth Advisors LLC raised its holdings in Arrowhead Pharmaceuticals by 80.6% during the second quarter. Carolina Wealth Advisors LLC now owns 345 shares of the biotechnology company's stock worth $28,000 after purchasing an additional 154 shares in the last quarter. Optiver Holding B.V. lifted its position in Arrowhead Pharmaceuticals by 83.8% in the first quarter. Optiver Holding B.V. now owns 408 shares of the biotechnology company's stock worth $26,000 after purchasing an additional 186 shares during the period. Persistent Asset Partners Ltd bought a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at $39,000. Finally, Allied Private Wealth LLC bought a new position in Arrowhead Pharmaceuticals during the 2nd quarter valued at $43,000. Institutional investors own 62.61% of the company's stock.

Arrowhead Pharmaceuticals Price Performance

Shares of Arrowhead Pharmaceuticals stock opened at $66.48 on Monday. Arrowhead Pharmaceuticals, Inc. has a 12-month low of $30.25 and a 12-month high of $95.49. The firm has a market capitalization of $9.36 billion, a PE ratio of -29.55 and a beta of 1.28. The company has a quick ratio of 5.90, a current ratio of 5.90 and a debt-to-equity ratio of 1.77. The stock's fifty day moving average is $82.93 and its 200-day moving average is $75.35.

Arrowhead Pharmaceuticals (NASDAQ:ARWR - Get Free Report) last released its quarterly earnings results on Tuesday, August 4th. The biotechnology company reported ($1.36) earnings per share for the quarter, missing analysts' consensus estimates of ($1.23) by ($0.13). The company had revenue of $75.25 million during the quarter, compared to analyst estimates of $44.17 million. Arrowhead Pharmaceuticals had a negative net margin of 47.79% and a negative return on equity of 60.06%. The company's revenue for the quarter was up 171.0% compared to the same quarter last year. During the same quarter last year, the business earned ($1.26) EPS. Equities analysts anticipate that Arrowhead Pharmaceuticals, Inc. will post -3.62 earnings per share for the current year.

Analyst Upgrades and Downgrades

ARWR has been the topic of several research analyst reports. HC Wainwright reiterated a "buy" rating and set a $120.00 price target on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, September 1st. Citigroup assumed coverage on Arrowhead Pharmaceuticals in a research note on Tuesday, September 8th. They set a "buy" rating and a $108.00 target price for the company. Stifel Nicolaus assumed coverage on Arrowhead Pharmaceuticals in a report on Tuesday, July 14th. They set a "buy" rating and a $98.00 target price on the stock. Leerink Partners boosted their price target on shares of Arrowhead Pharmaceuticals from $61.00 to $72.00 and gave the stock a "market perform" rating in a research report on Wednesday, June 17th. Finally, Morgan Stanley upped their price target on shares of Arrowhead Pharmaceuticals from $100.00 to $120.00 and gave the company an "overweight" rating in a report on Thursday, July 23rd. Ten equities research analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the company has an average rating of "Moderate Buy" and a consensus price target of $99.15.

Insider Buying and Selling

In other Arrowhead Pharmaceuticals news, Director Michael Perry sold 11,600 shares of the business's stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $87.30, for a total transaction of $1,012,680.00. Following the sale, the director directly owned 111,459 shares of the company's stock, valued at $9,730,370.70. The trade was a 9.43% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Adeoye Olukotun sold 2,000 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $86.96, for a total value of $173,920.00. Following the completion of the sale, the director owned 31,600 shares of the company's stock, valued at $2,747,936. The trade was a 5.95% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 3.60% of the company's stock.

Arrowhead Pharmaceuticals Profile

Arrowhead Pharmaceuticals, Inc NASDAQ: ARWR is a biopharmaceutical company focused on developing medicines that silence disease-causing genes. The company uses RNA interference (RNAi), a biological process that reduces the production of specific proteins, to target conditions that may be difficult to treat with conventional drugs.

Arrowhead's proprietary TRiM platform is designed to deliver RNAi-based therapies to different tissues, including the liver, lungs and other organs. Its investigational pipeline has included candidates for cardiovascular and metabolic diseases, liver disorders, pulmonary conditions and inflammatory diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.